Category Archives: Patently BIOtech

Recent Developments in Patentability: Prometheus and Myriad

supreme-court

By Joe Allen, President, Allen and Associates Recent Developments in Patentability: Prometheus and Myriad at the 2012 BIO International Convention was a very lively panel discussion on two cases that have set the life science industry on edge. The discussion presented an appropriate diversity of views as experts struggle with how broadly these cases should be interpreted. Briefly, the unanimous decision by the Supreme Court overtuning a decision upholding the Prometheus patents by the Court Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

From Bench to Bedside in a Bioeconomy

lab_tech02-btn

By Joe Allen, President, Allen and Associates It’s a sign of a well crafted program when the closing panel reinforces the opening speaker. Boston University President Robert Brown kicked off the afternoon at the Translational Research Forum at the 2012 BIO International Convention by showing how the old linear model of product development crafted after World War II no longer applies. The closing industry panel aptly remarked that a struggling economy has brought the public and private Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Measuring the Impact of Innovation

USPTO

By Joe Allen, President, Allen and Associates It’s always an indication of interest and importance in a topic when a panel draws a standing room only crowd. And that was the case with the Measuring the Impacts of Innovation: What is the Future of Tech Transfer? session at the 2012 BIO International Convention. The panel focused on the need to help policy makers, institutions and the public identify appropriate measures for how publicly funded R&D Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Gene Patent Discussion Should Include Industrial, Environmental, & Ag Biotech

myriad-more

Twenty-three industrial and agricultural biotech companies, ranging from development-stage businesses to all of the largest players in the field, sent a letter to the Solicitor General expressing concern over the pending appeal in the Myriad “gene patents” case.  The companies wrote the letter to correct the myopic view that this case is only about human genetic diagnostics. The case could potentially adversely impact agricultural and industrial biotechnology, whose activities are far removed from the clinical Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , ,

2012 BIO International Convention: Academic and Tech Transfer Community

2012bio-conv

Universities have historically been on the front lines of translating innovative research into novel medicines and technologies useful to patients.  With that in mind, the 2012 BIO International Convention will look to highlight the role of academia in the advancement of the biotechnology field through the BIO Academic Park and the Translational Research Forum. Hosted by the Biotechnology Industry Organization (BIO), this year’s global event for biotechnology will take place June 18-21, 2012 at the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , ,